Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71–84.

Article  CAS  PubMed  Google Scholar 

Banerjee R, Lee SS, Cowan AJ. Innovation in BCMA CAR-T therapy: building beyond the Model T. Front Oncol. 2022;12:1070353.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16.

Article  CAS  PubMed  Google Scholar 

Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41:4416–29.

Article  CAS  PubMed  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.

Article  CAS  PubMed  Google Scholar 

Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022;387:1196–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10:e107–e116.

Article  CAS  PubMed  Google Scholar 

Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti–G protein–coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial. J Clin Oncol. 2023;41:2583–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433–44.

Article  PubMed  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85–96.

Article  CAS  PubMed  Google Scholar 

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978–92.

Article  CAS  PubMed  Google Scholar 

Banerjee R, Marsal J, Huang CY, Lo M, Kambhampati S, Kennedy VE, et al. Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther. 2021;27:477.e1–477.e7.

Article  CAS  Google Scholar 

Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood. 2023. https://doi.org/10.1182/blood.2022017414

Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liberman AC, Budziñski ML, Sokn C, Gobbini RP, Steininger A, Arzt E. Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells. Front Endocrinol. 2018;9:235.

Article  Google Scholar 

Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transpl. 2021;21:2543–54.

Article  CAS  Google Scholar 

Hashmi H, McGann M, Greenwell BI. Use of long-term corticosteroids in patients treated with CAR T-cell therapy. J Oncol Pharm Pr. 2023;29:473–6.

Article  CAS  Google Scholar 

Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 2023;13:1982–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29:422–9.

Article  CAS  PubMed  Google Scholar 

Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.

Article  Google Scholar 

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software partners. J Biomed Inf. 2019;95:103208.

Article  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.

Article  PubMed  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38.

Article  CAS  Google Scholar 

Liang EC, Sidana S. Managing side effects: guidance for use of immunotherapies in multiple myeloma. Hematology. 2023;2023:348–56.

Article  PubMed  Google Scholar 

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.

Article  PubMed  PubMed Central  Google Scholar 

Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006;63:60.

Article  CAS  PubMed  Google Scholar 

Beyranvand Nejad E, Labrie C, Van Elsas MJ, Kleinovink JW, Mittrücker HW, Franken KLMC, et al. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. J Immunother Cancer. 2021;9:e002460.

Article  PubMed  PubMed Central  Google Scholar 

Sun Z, Xun R, Liu M, Wu X, Qu H. The association between glucocorticoid administration and the risk of impaired efficacy of axicabtagene ciloleucel treatment: a systematic review. Front Immunol. 2021;12:646450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6. https://doi.org/10.1126/scitranslmed.3008226

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5. https://doi.org/10.1126/scitranslmed.3005930

Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134:2149–58.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10:15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119–28.

Article  PubMed  PubMed Central  Google Scholar 

Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95:1324–33.

Article  CAS  PubMed  Google Scholar 

Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, et al. Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome. Biomolecules. 2023;13:382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luttwak E, Flynn JR, Devlin SM, Cassanello G, Corona M, Dahi PB, et al. Patterns and safety of glucocorticosteroids use following CD19 CAR-T cell therapy for B-cell lymphoma. Blood. 2023;142:4889–4889.

Article  Google Scholar 

Wang X, Qi Y, Li H, Liu F, Cao J, Chen W, et al. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy. Front Immunol. 2022;13:943004.

Article  CAS  PubMed  PubMed Central